Quantcast
Last updated on April 20, 2014 at 0:02 EDT

Latest famotidine Stories

2014-04-16 12:31:30

NORTHBROOK, Ill., April 16, 2014 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that it has reached an agreement with the U.S. Department of Justice to resolve civil claims regarding the marketing of MYCAMINE(®) (micafungin sodium) for injection. Under the agreement, Astellas will pay $7.3 million to the settling parties. The Department of Justice had investigated Astellas for alleged off-label...

2013-06-13 04:21:45

LONDON, June 13, 2013 /PRNewswire/ -- Magicool Plus(R) range of OTC topical, Class IIa sprays were recently listed in the NHS Drug Tariff part IX, under a specially created category and is available on prescription and OTC. The range comprises Magicool Plus(R) Prickly Heat, Magicool Plus(R) Itchy Skin due to Summer Ailments and Magicool Plus(R) Sunburn, for treating mild to severe forms of the respective conditions. (Logo:...

2013-01-02 12:22:35

WOODCLIFF LAKE, N.J., Jan. 2, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that its Par Pharmaceutical, Inc. operating subsidiary has begun shipping 5 mg and 10 mg strengths of rizatriptan benzoate tablets and 5 mg and 10 mg strengths of rizatriptan benzoate orally disintegrating tablets. Rizatriptan benzoate tablets and rizatriptan benzoate orally disintegrating tablets are each indicated for the acute treatment of migraine with or without aura in adults and in...

2012-10-01 02:30:32

DEERFIELD, Ill., Oct. 1, 2012 /PRNewswire/ -- Horizon Pharma, Inc. (NASDAQ: HZNP) announced today that it has completed the expansion of its sales force from 80 to 150 representatives. This expansion will allow increased reach and frequency of calls on physician targets for its lead product DUEXIS(®) (ibuprofen and famotidine), which is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal...

2012-09-28 02:24:27

DEERFIELD, Ill., Sept. 28, 2012 /PRNewswire/ -- Horizon Pharma, Inc. (NASDAQ: HZNP), announced today that it has received Notices of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application Serial No. 13/403,930 and U.S. Application Serial No. 13/403,923 both entitled "Stable Compositions of Famotidine and Ibuprofen" with claims that cover DUEXIS(®) (ibuprofen and famotidine) tablets. DUEXIS is indicated for the relief of signs and symptoms of...

2012-06-18 02:26:29

DEERFIELD, Ill., June 18, 2012 /PRNewswire/ -- Horizon Pharma, Inc. (NASDAQ: HZNP) and Mallinckrodt LLC the Pharmaceuticals business of Covidien (NYSE: COV), announced today that they have entered into a U.S. co-promotion agreement for DUEXIS® (ibuprofen and famotidine), which is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers. "This collaboration with Mallinckrodt will expand...

2010-07-01 10:55:00

BALTIMORE, July 1 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the US Food and Drug Administration (FDA) for its Famotidine for Oral Suspension (40 mg / 5 mL). Commercial shipments of the product have already commenced. Lupin's Famotidine for Oral Suspension is the AB-rated generic equivalent of Merck's *PEPCID® indicated for the short-term treatment of active duodenal ulcer, active benign gastric ulcer, and...

2010-06-09 08:00:00

NORTHBROOK, Ill., June 9 /PRNewswire/ -- Horizon Pharma, Inc., today announced that data on its two lead product candidates, LODOTRA®, a circadian cytokine modulator and novel modified release, low-dose prednisone tablet, and DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, will be presented during the European League Against Rheumatism (EULAR) Annual Congress taking place in Rome, Italy,...

2010-05-26 08:00:00

NORTHBROOK, Ill., May 26 /PRNewswire/ -- Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S. Food and Drug Administration (FDA) for review. Horizon is...

2010-04-01 13:30:00

NORTHBROOK, Ill. and REINACH, Switzerland, April 1 /PRNewswire/ -- Horizon Therapeutics, Inc. and Nitec Pharma AG, both privately held companies, today announced a definitive agreement in which the two companies have combined in an all-stock transaction. The combined company also completed a concurrent preferred stock financing in conjunction with the transaction. The combined company will be named Horizon Pharma, Inc., and will be led by Timothy P. Walbert, previously president and...